Cargando…
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
Background: Meropenem is being investigated for repurposing as an anti-tuberculosis drug. This study aimed to develop a meropenem population pharmacokinetics model in patients with pulmonary tuberculosis and identify covariates explaining inter-individual variability. Methods: Patients were randomiz...
Autores principales: | Abulfathi, Ahmed A., de Jager, Veronique, van Brakel, Elana, Reuter, Helmuth, Gupte, Nikhil, Vanker, Naadira, Barnes, Grace L., Nuermberger, Eric, Dorman, Susan E., Diacon, Andreas H., Dooley, Kelly E., Svensson, Elin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275874/ https://www.ncbi.nlm.nih.gov/pubmed/34267655 http://dx.doi.org/10.3389/fphar.2021.637618 |
Ejemplares similares
-
Optimizing β-Lactams against Tuberculosis
por: de Jager, Veronique R., et al.
Publicado: (2020) -
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021) -
Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Dooley, Kelly E., et al.
Publicado: (2020) -
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020) -
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)